Thyroid Nodules — When Should You Worry?

A thyroid nodule is any circumscribed change in thyroid tissue that differs in structure from the surrounding parenchyma — it may be solitary or one of many within what's known as a multinodular goiter. Nodules are relatively rare to feel on physical examination, but when high-frequency ultrasound is used for evaluation, the picture changes drastically: population studies show that thyroid nodules can be detected in a substantial share, and in some studies even the majority, of adults examined, with frequency rising markedly with age.

The thyroid consists of millions of follicles that secrete hormones under the influence of TSH from the pituitary gland. Nodules form when certain areas of tissue begin to grow independently of the rest of the gland — most often as a result of benign proliferation of follicular cells (colloid adenoma, hyperplastic nodule), fluid accumulation in a post-follicular space (cyst), a chronic inflammatory process in the course of Hashimoto's disease (described in more detail in our article on hypothyroidism), or, less commonly, uncontrolled neoplastic growth.

Some nodules are so-called autonomous nodules — tissue that produces thyroid hormones independently of TSH regulation, which in larger sizes can lead to hyperthyroidism. Chronic iodine deficiency, or less commonly excess, also matters — a topic we discuss in more detail in another article — in regions with iodine deficiency, multinodular goiter is significantly more common, though in Poland, after the salt-iodization program, this factor is less significant today than several decades ago.

The key clinical question for any newly detected nodule, then, isn't "is this something," because a nodule is by definition already a visible, distinct lesion — it's: what is the probability that this particular lesion is malignant, and how can that probability best be estimated without subjecting every patient to unnecessary, invasive diagnostics.

The answer to that question is a structured ultrasound assessment. For decades, different radiologists described thyroid nodules inconsistently, which made it difficult to compare results and make consistent biopsy decisions. In 2017, the American College of Radiology (ACR) published the TI-RADS (Thyroid Imaging Reporting and Data System), which standardized this assessment.

In practice, this means that an ultrasound report on a thyroid nodule today, at many centers, includes a specific TI-RADS category rather than just a descriptive "suspicious nodule" or "non-suspicious nodule." This is an important change — the biopsy decision no longer depends solely on the subjective impression of the person performing the exam, but on a standardized score that can be compared between centers.

An important caveat: no single feature is diagnostic on its own — that's exactly why the TI-RADS scoring system was created, combining several features at once, since a single feature assessed subjectively has limited predictive value. Large fluid-filled nodules (cysts) and spongiform-structured nodules (numerous small fluid-filled spaces), on the other hand, have very low malignancy risk regardless of size, which often allows biopsy to be avoided even for relatively large lesions.

When the sonographic features and size of a nodule indicate a need for further workup, the standard is ultrasound-guided fine-needle aspiration biopsy (FNA) — a short, outpatient procedure involving the collection of cellular material without the need for general anesthesia. The collected material is assessed using the Bethesda classification, a six-tier scale covering categories from "non-diagnostic" through "benign lesion," "atypia of undetermined significance," up to "suspicious for malignancy" and "malignant."

Since the 1980s, the number of thyroid cancer diagnoses has been rising steadily in many countries — in the United States, incidence has increased by as much as around 250% since 1990. At first glance, this looks like an alarming trend. Closer analysis shows something different, however: thyroid-cancer-related mortality has stayed practically unchanged over the same period, and the growing number of diagnoses concerns almost exclusively small, asymptomatic forms of papillary carcinoma (microcarcinoma, ≤1 cm), detected mainly incidentally during ultrasound performed for other reasons.

A consequence of this observation is a shift in the approach to small, low-risk papillary carcinomas (microcarcinoma). In Japan, as part of the Kuma Hospital protocol, research into active surveillance (observation without immediate surgery) of such lesions has been conducted since the 1990s.

The opposite extreme can be just as problematic: completely ignoring the information about a nodule, with no further evaluation at all, isn't a reasonable approach either — even a small malignancy percentage in a population where nodules are as common as thyroid nodules translates, in absolute numbers, into a real number of cases requiring treatment. A reasonable approach lies between panic and complete neglect: a structured ultrasound assessment and, where indicated, biopsy, without catastrophizing the mere fact that a lesion exists.

If hypothyroidism from Hashimoto's disease coexists alongside a nodule, treatment with levothyroxine follows from the hypothyroidism itself (normalizing TSH), not from a desire to "treat" the nodule as such — an important clinical distinction that's easy to conflate when reading information online.

Thyroid nodules are a good example of how easily the mere frequency of detecting a medical phenomenon can be read as a rise in its danger, when in reality it mainly reflects the sensitivity of today's imaging diagnostics. Structured assessment systems like TI-RADS and evidence-based ATA guidelines now make it possible to distinguish nodules requiring further workup from those that can be safely observed — without needing to biopsy every detected lesion.

A reasonable approach to a newly detected thyroid nodule isn't to ignore it, but also not to catastrophize the mere fact of its existence. It's worth asking for the specific risk category in the ultrasound report, understanding the reasoning behind the recommended next step, and, if in doubt, seeking a second opinion — rather than looking for answers in supplements or diets with no confirmed effect on nodular tissue.